Загрузка...
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Chinês |
| Опубликовано: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
| Серии: | Chinese Journal of Lung Cancer |
| Предметы: | |
| Online-ссылка: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|